Altretamine for the Treatment of Metastatic Renal Cell Carcinoma – A Hoosier Oncology Group Trial

Authors: Zon R.T.1; McClean J.2; Helman D.3; Ansari R.1; Picus J.4; Sandler A.3; Williams S.D.3; Loehrer Sr. P.J.5

Source: Investigational New Drugs, Volume 19, Number 3, August 2001 , pp. 229-231(3)

Publisher: Springer

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Thirty patients with advanced renal cell carcinoma were treated on a phase 11 trial with altretamine. Altretamine was administered orally at a dosage of 260 mg/m² days 1 through 14 with cycles repeated every 28 days. Nausea and vomiting were the most common toxicities. Ten percent (3 of 30) experienced Grade 3 gait abnormalities. None of the thirty evaluable patients achieved a complete or partial response. In summary, altretamine did not show antitumor activity in the treatment of advanced renal cell carcinoma.

Keywords: altretamine; renal cell carcinoma

Language: English

Document Type: Regular paper

Affiliations: 1: Northern Indian Cancer Research Consortium, South Bend, IN, USA 2: The Cottage Professional Building, Galesburg, USA 3: Indiana University Cancer Center, Indianapolis, USA 4: Washington University/Barnard Cancer Center, St. Louis, MO, USA 5: Indiana University Cancer Center, Indianapolis, USA; The Walther Oncology Institute, Indianapolis, IN, USA

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$47.00 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A